MARK SMITH: Open Payments
NPI 1063432284 · GAITHERSBURG, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$899 in 63 payments from 10 companies in 2025. Trend: 2023 $1,286 · 2024 $1,458 · 2025 $899
Food & beverage: $899
| Company | Payments | Amount |
|---|---|---|
| Lundbeck LLC | 10 | $184 |
| ABBVIE INC. | 13 | $182 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 17 | $173 |
| Otsuka America Pharmaceutical, Inc. | 12 | $147 |
| Vanda Pharmaceuticals Inc. | 4 | $72 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $45 |
| Collegium Pharmaceutical, Inc. | 2 | $34 |
| Lilly USA, LLC | 1 | $27 |
| Vertical Pharmaceuticals, LLC | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $15 |
Products named: REXULTI, CAPLYTA, VRAYLAR, FANAPT, ABILIFY ASIMTUFII, TRINTELLIX, Jornay PM, ABILIFY MAINTENA.
Industry payments across MD — which companies pay providers there.
